Drug and Therapeutics Bulletin 1995;33:1-3; doi:10.1136/dtb.1995.3311
Copyright © 1995 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Who needs nine ACE inhibitors?

Relevant BNF section: 2.5.5

Nine angiotensin-converting enzyme (ACE) inhibitors are now marketed in the UK. The first, captopril, was introduced in 1981.1 Then followed enalapril,2 lisinopril,3 quinapril, perindopril and ramipril4 and, most recently, cilazapril, fosinopril and {blacktriangledown}trandolapril. Their place in the treatment of patients with heart failure5,6 and hypertension7 is now established, and a new indication as part of the treatment of myocardial infarction is increasingly being recognised. In this article we review the ACE inhibitors and ask if all nine are really needed.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1995 BMJ Publishing Group Ltd.